Kymera Therapeutics Announces Major Public Offering
WATERTOWN, Mass. — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has revealed plans for a substantial public offering of common stock, estimated to be around $200 million. This offering will consist of common stock shares and, for certain investors, pre-funded warrants that allow for the purchase of additional shares. The company also intends to give underwriters a 30-day option to acquire up to $30 million in extra shares at the public offering price, not including underwriting fees and commissions.
This initiative is designed to support the clinical progress of Kymera's protein degradation programs, which aim to tackle significant health challenges faced by patients around the world. The funds raised will be vital for enhancing the company’s research and development efforts, as well as expanding its pipeline of innovative solutions that show strong commercial potential.
Kymera Therapeutics is dedicated to developing medicines through targeted protein degradation (TPD), a groundbreaking scientific method that enables the targeting of disease pathways that were previously unreachable. The company has made notable strides by advancing its first degrader into clinical trials for immunological diseases and is actively pursuing oncology programs aimed at addressing difficult cancer proteins.
This public offering will be conducted under an automatically effective shelf registration statement that has been filed with the U.S. Securities and Exchange Commission (SEC). A prospectus supplement will be made available to detail the specific terms of the offering.
As stated in the announcement, prominent investment banks Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are serving as joint book-running managers for this public offering. The financing will not only help advance clinical programs but will also be used for general corporate purposes, including potential partnerships or investments in complementary technologies.
Kymera's innovative approach continues to gain recognition within the biotech community, further enhanced by its status as one of Boston’s leading workplaces over the years. By focusing on novel degradation therapeutics, Kymera aims to revolutionize the treatment landscape for chronic conditions and significantly improve patients' quality of life.
About Kymera Therapeutics
Founded in 2016, Kymera Therapeutics is at the cutting edge of biotechnology, concentrating on targeted protein degradation to create treatments that address urgent health challenges. Their groundbreaking work targets diseases that traditional therapies cannot reach, establishing them as a key player in the industry. The company is committed to developing convenient and highly effective oral treatments, particularly for complex conditions such as cancer and autoimmune disorders.
Contact Information
If you have any inquiries, please contact:
Justine Koenigsberg
Vice President, Investor Relations
Email: investors@kymeratx.com
Media: media@kymeratx.com
Phone: 857-285-5300
Frequently Asked Questions
1. What is Kymera Therapeutics planning to do with the public offering?
Kymera Therapeutics plans to utilize the proceeds from the public offering to further its pipeline of targeted protein degradation programs, as well as for general corporate purposes.
2. How much money is Kymera Therapeutics aiming to raise?
The company is seeking to raise approximately $200 million through this public offering.
3. Which banks are facilitating the offering?
Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers for the public offering.
4. What is the significance of targeted protein degradation?
Targeted protein degradation represents a novel strategy for treating diseases by enabling the targeting of challenging disease pathways that traditional therapies cannot access.
5. What has been Kymera's recognition in the biotech sector?
Kymera Therapeutics has been recognized as one of Boston’s top workplaces for several years, showcasing its innovative culture and dedication to advancing healthcare.
